Get the Stockscreener App
347.94
1.51%
-5.34
Pre-market:
347.47
-0.47
-0.14%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $347.94, with a volume of 1.60M.
It is down -1.51% in the last 24 hours and down -9.79% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$353.28
Open:
$352.72
24h Volume:
1.60M
Relative Volume:
0.58
Market Cap:
$187.56B
Revenue:
$36.74B
Net Income/Loss:
$7.71B
P/E Ratio:
24.45
EPS:
14.2333
Net Cash Flow:
$8.10B
1W Performance:
-1.48%
1M Performance:
-9.79%
6M Performance:
+16.99%
1Y Performance:
+13.82%
1-Day Range:
$345.87
$354.16
1-Week Range:
$345.87
$357.00
52-Week Range:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
347.94 | 187.56B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34 - TradingView
Amgen Inc. $AMGN Position Boosted by JB Capital LLC - MarketBeat
A Look At Amgen (AMGN) Valuation After New Repatha Data And Zai Lab Oncology Collaboration - simplywall.st
Amgen Inc. (AMGN) stock price, news, quote and history - Yahoo Finance UK
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN - MarketBeat
SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - indexbox.io
Amgen Beats Estimates by $400 Million in Q4: Here’s Why Analysts Target $350 - TIKR.com
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study - TipRanks
Dorato Capital Management Invests $1.58 Million in Amgen Inc. $AMGN - MarketBeat
Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN - MarketBeat
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile - Yahoo Finance
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Australia
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory - The Motley Fool
Amgen's Diversification Continues To Pay Off, RBC Says - Moomoo
Turning Up the Volume on IgG4-RD Awareness and Diagnosis - Amgen
Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next - tipranks.com
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? - Insider Monkey
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $390 - Moomoo
HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN - MarketBeat
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - Yahoo Finance
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: ReportAmgen (NASDAQ:AM - Benzinga
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy - AASTOCKS.com
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative? - simplywall.st
AMGEN INC (AMGNCL.SN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Amgen Inc. Stock: Biotech Leader's Strategic Pipeline and Oncology Focus Drive Long-Term Investor Va - AD HOC NEWS
Zai Lab gains after Amgen clinical trial deal (ZLAB:NASDAQ) - Seeking Alpha
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen (AMGN) and Zai Lab Partner for Lung Cancer Treatment Study - gurufocus.com
Once the center of a $3.7 billion buyout, drug blamed for eight deaths draws FDA alert - The Business Journals
Zai Lab Limited and Amgen Inc Enter Global Clinical Trial Collaboration Agreement - marketscreener.com
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $432 - Moomoo
A two-drug small cell lung cancer trial pairs Amgen with Zai Lab - Stock Titan
Highline Wealth Partners LLC Sells 4,004 Shares of Amgen Inc. $AMGN - MarketBeat
Nisa Investment Advisors LLC Has $55.22 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Amgen Inc. $AMGN Shares Bought by Moody Lynn & Lieberson LLC - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Amgen Inc. (0R0T.IL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openpr.com
BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Average Rating of "Hold" by Analysts - MarketBeat
FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths - wsj.com
US FDA warns of liver injury cases tied to Amgen's rare disease drug - Reuters
FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos UseAmgen (NASDAQ:AMGN) - Benzinga
FDA Flags Serious Liver Risks with Amgen's Tavneos (AMGN) - GuruFocus
FDA issues warning for Amgen's Tavneos following serious liver injury cases - Seeking Alpha
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):